Biosplice Therapeutics Is A Clinical Stage Biotechnology Company Based In San Diegocaliforniafounded In 2008The Company Focuses On Developing Therapeutics That Modulate Alternative Pre Mrna Splicing To Address Significant Diseasestheir Innovative Approach Targets The Clk Dyrk Family Kinaseswhich Play A Crucial Role In Rna Splice Site Selectionaiming To Reprogram Cellular Behavior And Produce Beneficial Protein Variants The Company Utilizes Small Molecule Inhibitors To Alter Splicing Patternsallowing For The Selective Elimination Of Harmful Proteinsbiosplice S Clinical Pipeline Includes Programs In Osteoarthritisoncologyand Neurologywith A Mission To Develop First In Class Therapies That Correct Dysregulated Splicingwith A Total Funding Of $561 5 Millionbiosplice Is Positioned As A Leader In Precision Medicinefocusing On Degenerative And Proliferative Diseases
